ASCENDIS PHARMA A/S
Ownership & governance
Executives 5Directors 7Avg age 59Avg tenure 8.4y
JM
Jan Mikkelsen
Chief Executive Officer
Age 67Since 2007-11-30
+11
Executives5
JM
Jan Mikkelsen
Chief Executive Officer
Age 67Since 2007-11-30
SS
Scott Thomas Smith
Director of Finance/CFO
Age 53Since 2016-08-07
AS
Aimee Shu
Chief Tech/Sci/R&D Officer
Age 50Since 2017-06-30
SS
Stina Singel
Chief Tech/Sci/R&D Officer
Age 53Since 2020-04-30
KS
Kennett Sprogøe
Chief Tech/Sci/R&D Officer
Age 48Since 2018-12-31
Board of directors7
JM
Jan Mikkelsen
Director/Board Member
Age 67Since 2007-11-30
AC
Albert Cha
Chairman
Age 54Since 2021-05-27
LB
Lisa Bright
Director/Board Member
Age 59Since 2017-03-31
LH
Lars Holtug
Director/Board Member
Age 68Since 2018-11-01
WF
William Fairey
Director/Board Member
Age 62Since 2022-08-31
SI
Siham Imani
Director/Board Member
Age 49Since 2022-08-31
JB
Jean-Jacques Bienaimé
Director/Board Member
Age 72Since 2026-03-22
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| RA Capital Management LP | 16.48 % | 10,281,496 |
| T. Rowe Price Investment Management, Inc. | 10.43 % | 6,506,219 |
| T. Rowe Price Investment Management, Inc. | 9.879 % | 6,162,042 |
| Avoro Capital Advisor LLC | 8.116 % | 5,062,500 |
| Westfield Capital Management Co. LP | 7.717 % | 4,813,440 |
Catalog · 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 308.39Range 262.54–350.3Analysts 20
262.54Mean 308.39350.3
- Strong buy 5
- Buy 15
Broker actions40 of 233
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Reiterated | Overweight | 300 | 2026-09-25 |
| Raymond James | Downgrade | Outperform | 287 | 2026-09-15 |
| Oppenheimer | Maintained | Outperform | 312 | 2026-09-02 |
| Morgan Stanley | Maintained | Overweight | 273 | 2026-09-01 |
| Wedbush | Reiterated | Outperform | 327 | 2026-09-01 |
| B of A Securities | Maintained | Buy | 304 | 2026-08-31 |
| Jefferies | Maintained | Buy | 330 | 2026-08-31 |
| Stifel | Maintained | Buy | 326 | 2026-08-31 |
| HC Wainwright & Co. | Maintained | Buy | 344 | 2026-08-31 |
| HC Wainwright & Co. | Initiated | Buy | 345 | 2026-08-27 |
| BMO Capital | Initiated | Outperform | 319 | 2026-08-19 |
| TD Cowen | Maintained | Buy | 341 | 2026-08-14 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.